Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem

Somerset, N.J. (PRWEB) December 04, 2014

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement with Swiss-based development-stage biopharmaceutical company SELLAS Life Sciences Group (SELLAS), to…

Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem

Somerset, N.J. (PRWEB) December 04, 2014

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement with Swiss-based development-stage biopharmaceutical company SELLAS Life Sciences Group (SELLAS), to…